Sharp rise in RT-PCR tests in Mumbai, Pune & other cities in Maharashtra: Metropolis Healthcare

A very sharp rise is seen in RT-PCR tests (reverse transcription-polymerase chain reaction) in Mumbai, Pune, and other cities in Maharashtra, said Ameera Shah, promoter and managing director (MD) of Metropolis Healthcare, on Tuesday.

Speaking in an interview with CNBC-TV18, she said, “We have seen a very sudden surge in COVID PCR infections and in tests that are required in Mumbai, Pune, and in some other parts of Maharashtra. There are only a few labs which are approved in Mumbai, so the ones which are approved are brim to the full capacity.”

“Metropolis has enhanced its capacity in the last week and we now have renewed capacity and therefore, all our centres are open. We are providing home visits, and we are able to take and absorb more capacity again,” she said.

Talking about the shortage of testing kits, Shah said, “Right now there is no shortage of kits, that’s reasonably comfortable. We are able to get machines, we are able to get kits. The hardest part is manpower because the ability when you are scaling up to identify manpower, to recruit manpower, to train them, and to put them on the job in two weeks is a herculean task.”

For the entire management interview, watch the video

 5 Minutes Read

HC asks AAP govt about protocols for disposal of used COVID-19 test kits

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The direction came on a PIL by a lawyer alleging improper disposal of used swabs from Rapid Antigen testing for COVID-19 at the office of the District Magistrate (South East Delhi) at Lajpat Nagar.

The Delhi High Court Tuesday asked the AAP government as to what guidelines or protocols were in place for disposal of used COVID-19 testing kits and whether they were being followed by the hospitals, clinics and doctors under its jurisdiction. A bench of Chief Justice D N Patel and Justice Prateek Jalan asked the Delhi government additional standing counsel Sanjoy Ghose and advocate Naman Jain to find out the guidelines or protocols in place, the authority which issued them and whether they were being implemented.

”Come with instructions,” the bench said to the Delhi government counsels and listed the matter for hearing on December 3. The direction came on a PIL by a lawyer alleging improper disposal of used swabs from Rapid Antigen testing for COVID-19 at the office of the District Magistrate (South East Delhi) at Lajpat Nagar.

The petitioner, Pankaj Mehta, has alleged that used swabs were being ”thrown out in public” and ”tests were being carried out over a pile of used swabs for COVID-19” at the DM’s office. ”Upon complaining about the risk of widespread infection and the irregularity behind disposing off the swabs in this manner, the concerned doctor at the counter said that the swabs are of negative patients and thus it is safe to stand over them and get yourself tested,” Mehta has claimed in his plea.

The claims and allegations were refuted by Ghose who said he was informed that the swabs being referred to in the plea were unused or defective. Ghose also said that he will nevertheless take instructions on the correct position and inform the court.

During the hearing, the court was also told by the Delhi government counsels that there are guidelines issued by the Delhi Pollution Control Committee (DPCC) with regard to disposal of medical waste. Mehta, in his petition, has said that the Union Health Ministry came out with the Clinical Management Protocol notification on July 3 which laid emphasis on safe waste management and cleaning of the environment across all the areas of healthcare facilities, but the same was not being allegedly enforced by the Delhi government.

Click here: For the latest news and updates on COVID-19

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

10 things you need to know before the opening bell on October 21

NSE, BSE, NSE special trading session, NSE Saturday session, BSE special trading session, BSE Saturday session, stock exchange open, special trading session, when is special trading session, special trading session timings,
Cherry blossoms bloom in front of a stock quotation board outside a brokerage in Tokyo
1. Asia: Stocks in Asia-Pacific rose in Wednesday morning trade as investors continue to watch for developments on U.S. coronavirus stimulus. In Japan, the Nikkei 225 added 0.36 percent in early trade while the Topix index gained 0.94 percent. South Korea’s Kospi rose 0.35 percent. Meanwhile, shares in Australia edged higher, with the S&P/ASX 200 up 0.19 percent. MSCI’s broadest index of Asia-Pacific shares outside Japan traded 0.11 percent higher, reported CNBC International. (Image: Reuters)
2. US: U.S. stock index futures rose in overnight trading on Tuesday after White House Chief of Staff Mark Meadows said that House Speaker Nancy Pelosi and Treasury Secretary Steven Mnuchin have made “good progress” on stimulus talks, before adding that they “still have a ways to go” before an agreement is reached. Futures contracts tied to the Dow Jones Industrial Average rose 124 points, indicating a more than 100-point rally at the open on Wednesday. S&P 500 futures traded 0.5 percent higher, while Nasdaq 100 futures advanced 0.6 percent, reported CNBC International. (Image: Reuters)
Sensex, Nifty, Bank Nifty, Nifty IT, Nifty FMCG, Nifty Auto, Nifty Metal, HDFC, HDFC Bank, Reliance Industries, TCS, Hindustan Unilever, BSE India, NSE India, Markets Today, Market News
3. Closing Bell: Indian indices ended higher on Tuesday mainly led by IT stocks and some financials after the banking index turned positive. Heavyweights HDFC Bank, Infosys, HCL Tech, TCS, and Asian Paints contributed the most to the benchmarks in today’s trade. The Sensex ended 113 points higher at 40,544 while the Nifty rose 24 points to settle at 11,897. Broader markets outperformed benchmarks with Nifty Midcap and Nifty Smallcap rising 0.6 percent and 0.4 percent, respectively. Among sectors, Nifty Realty surged over 4 percent and Nifty IT added 1.4 percent. Nifty Bank, Nifty Auto and Nifty Pharma also ended the day in the green. (Image: Reuters)
4. Crude Oil: Oil edged up on Tuesday on hopes that the United States was nearing a stimulus deal, but the threat to demand from rising coronavirus cases worldwide and increased Libyan output kept prices from moving higher. Brent crude futures gained 20 cents to $42.82 a barrel. November U.S. West Texas Intermediate crude futures settled 63 cents, or 1.54 percent, higher at $41.46 per barrel, reported CNBC International. (Image: Reuters)
7th Pay Commission: Jammu and Kashmir and Ladakh
5. Rupee Close: The Indian currency depreciated 12 paise to close at 73.49 against the US currency due to the dollar buying by state-run banks amid increased forex inflows. Capital inflows and strong domestic equities, however, limited the local currency’s losses, said PTI. (Image: Reuters)
6. India Considering To Remove Plasma Therapy From Guidelines: In what could leave a huge gap in COVID-19 investigational therapies, the Indian Council of Medical Research (ICMR) and the national task force is considering to delete convalescent plasma therapy from its national COVID-19 treatment protocol guidelines. The decision, if taken, will be based on clinical trials conducted by ICMR that showed plasma therapy did not reduce COVID-19 mortality or disease progression. Convalescent plasma therapy at present is listed as “off-label” use and as an investigational therapy in national guidelines. In a press briefing, Director General of ICMR Dr Balram Bhargava said, “We have done a large clinical trial on plasma, it will be published in the British Journal. Discussing within the task force on may be deleting plasma therapy from our national covid19 treatment guidelines.” (Image: PTI)
7. Delays In Customs Clearance Cripple Import-Export Industry: Customs clearance delays continue to cripple the Indian industry as they have extended from the earlier 15-20 days to 25-30 days, and in some cases clearance is being given after over a month, sources told CNBC-TV18. The industry and custom brokers are citing the poor rollout of faceless assessment for the delays. The sectors that are being impacted by the delay has expanded. Earlier, delays were faced primarily by automobiles, auto ancillary, electrical machinery, metals, chemicals and medical equipment. However, now labour intensive sectors and domestic manufacturing are also getting impacted, due to the delay in release of goods. According to export agencies, the delay is worsening the situation as the current period is peak business time ahead of the Christmas break. Export agencies have claimed that there are no containers available and freight rates have shot up substantially. They believe that there is an urgent need for regulatory body to regulate the operations. (Image: Reuters)
Sales of manufacturing cos contracted 41.1 pc in Q1: RBI
8. Sales Of Manufacturing Companies Contracted: Aggregate sales of private sector manufacturing companies recorded a sharp contraction of 41.1 percent year-on-year in the first quarter of 2020-21, reflecting the impact of the pandemic induced lockdown, said an RBI analysis on Tuesday. The data on the performance of the private corporate sector during the first quarter of 2020-21 has been drawn from abridged quarterly financial results of 2,5361 listed non-government non-financial (NGNF) companies, the RBI said. “Aggregate sales of 1,619 manufacturing companies recorded a sharp contraction of 41.1 percent (Y-o-Y) in Q1:2020-21 following 15.6 percent decline in Q4:2019-20 reflecting the impact of the pandemic induced lockdown,” it said. (Image: Reuters)
9. WEF On Recession And Automation: The Future of Jobs 2020 report has found that COVID-19 has caused the labour market to change faster than expected. The research released today by the World Economic Forum indicates that what used to be considered the “future of work” has already arrived. By 2025, automation and a new division of labour between humans and machines will disrupt 85 million jobs globally in medium and large businesses across 15 industries and 26 economies. Roles in areas such as data entry, accounting and administrative support are decreasing in demand as automation and digitization in the workplace increases. More than 80% of business executives are accelerating plans to digitize work processes and deploy new technologies; and 50% of employers are expecting to accelerate the automation of some roles in their companies. In contrast to previous years, job creation is now slowing while job destruction is accelerating. (Image: Reuters)
10. Siemens Healthineers To Make COVID Testing Kits: German medical tech company Siemens Healthineers is in the process of expanding its manufacturing capacity in India to locally produce testing kits for diagnosing COVID-19. The company has also applied for a licence for its newly launched rapid antigen test kit with the ICMR and is awaiting approval, Vivek Kanade, executive vice president for Siemens Healthineers In India, told CNBC TV 18. “We are expanding our manufacturing plant in Baroda to locally manufacture testing kits. Currently, all of these are being imported from our factories in Europe and US,” Kanade said. The plant is currently manufacturing reagents and entry-level blood analysers. (Image: Reuters)
 5 Minutes Read

Ready for any review by ICMR, say Chinese testing kit manufacturers

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Days after the Indian Council of Medical Research asked states not to use Chinese testing kits till the time they had been thoroughly checked, Chinese manufacturers have said they are ready for any re-evaluation and are in touch with ICMR.

Days after the Indian Council of Medical Research asked states not to use Chinese testing kits till the time they had been thoroughly checked, Chinese manufacturers have said they are ready for any re-evaluation and are in touch with ICMR.

“Wondfo Biotech took immediate actions to investigate and understand the issue. We will fully co-operate with ICMR review and any re-testing arrangements. Safety & product quality are our highest priorities,” said the Guangzhou-based company.

Wondfo Biotech & Livzon Diagnostics are among the firms that are exporting test kits to India. India has received 3 lakh testing kits from Wondfo and 2.5 lakh testing kits from Livzon.

On Thursday, the spokesperson for the Ministry of External Affairs, Anurag Srivastava, said, “In the past two weeks, around two dozen flights departed for India from five cities in China carrying nearly 400 tonnes of medical supplies, including RT-PCR test kits, Rapid Antibody Tests, PPE kits, thermometers, etc. Around 20 more flights are expected to bring supplies from China in the coming days, and this is likely to be stepped up considerably in the next few months as our procurement efforts gain momentum.”

Both the Chinese companies said that their products had been validated by ICMR and evaluated at National Institute of Virology, Pune.

“We at Livzon diagnostics are shocked to receive negative reports from the Indian media related to poor accuracy of COVID-19 rapid test kits made in China. We have shown great concern on the issue and are willing to co-operate with the Indian government for any investigation,” said Livzon Diagnostics in a statement.

Read: COVID-19 brings back focus on India’s dependency on China for drug raw materials

Wondfo Biotech said that its products had been exported to more than 70 countries while Livzon Diagnostics has said that its products have been used in more than 13 countries.

Both companies said there can be variations in results during the window period, which is the gap between infection and appearance of anti body. “Negative results do not rule out coronavirus infection, especially in those who have come in contact with the virus. Follow-up anti body tests combined with molecular testing should be considered to rule out infection,” said Livzon Diagnostics. The company also said that anti body testing kits should not be the sole basis for diagnosing coronavirus.

The Chinese manufacturers have sent letters to the ICMR stating the conditions under which the kits should be used and possible reasons for variations.

According to reports, several European countries have raised concerns about quality of test kits manufactured in China and their accuracy.

On Tuesday, the Chinese Embassy Spokesperson Ji Rong said, “Noticed reports concerning rapid testing kits. China attaches great importance to the quality of exported medical products. Will keep close communication with concerned Indian agency and provide necessary assistance.”

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

India received 5 lakh rapid COVID-19 testing kits from China: Health Ministry

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

According to the health ministry, the death toll due to the novel coronavirus rose to 420 with 28 fatalities reported since Wednesday evening, while the number of cases saw a jump of 826 to go up to 12,759 cases on Thursday.

India has received the much-awaited five lakh rapid COVID-19 testing kits from China and these are not meant for an early diagnosis of the disease rather for monitoring whether coronavirus hotspots in India are increasing or showing a declining trend, the government said on Thursday.

Addressing a daily briefing on COVID-19 situation in the country, chief of Epidemiology and Communicable Diseases at ICMR Dr Raman R Gangakhedkar said the serologic rapid testing kits have been provided by two Chinese companies.

“These kits will be used to check antibodies which the body of a person prepares as a weapon to fight a virus. There are different types of antibodies, one of which is immunoglobulin M (IgM) that does not stay for more than a few days and spotting of IgM antibody means the infection is recent, he said.

Whereas, detection of immunoglobulin G (IgG) antibody indicates that our immune system is improving. If only IgG and no IgM antibody is detected, it is assumed to be an old infection, Dr Gangakhedkar explained.

He said the rapid antibody test kits procured are not meant for early diagnosis, but “only for surveillance and trend checking”.

“The tests can be done periodically to see the trend. If we do an antibody test say after around two weeks, these will appear in only 80 percent of the people. That is why these tests are not used for early diagnosis but are for surveillance,” the ICMR official said.

Till date, RT-PCR is the ultimate test for the detection of novel coronavirus, he asserted.

About reports suggesting that such kits are faulty, Dr Gangakhedkar acknowledged that the sensitivity and specificity of these are less.

“Since rapid antibody tests are for monitoring and surveillance, there is no concern with respect to the testing kits being faulty. That concern was with respect to immune response alone,” he explained.

He further said that 2,90,401 samples have been tested so far, of which 30,043 were tested on Wednesday itself.

Out of the tests carried out on Wednesday, 26,331 were done in laboratories under Indian Council of Medical Research (ICMR) network and 3,712 in private labs, he added.

Commenting on the testing capacity of ICMR network, the official said, “Working in one shift, more than 42,400 samples can be tested each day. If we work in two shifts, we will be able to test more than 78,200 samples daily.”

Dr Gangakhedkar further talked about the use of doing pooled testing which, he said, will reduce cost and yield the same result. This can be done in areas where positivity rate is low, he added.

According to the health ministry, the death toll due to the novel coronavirus rose to 420 with 28 fatalities reported since Wednesday evening, while the number of cases saw a jump of 826 to go up to 12,759 cases on Thursday.

On Thursday afternoon, Joint Secretary in the Health Ministry Lav Agarwal said, “If our case fatality rate is 3.3 percent then the percentage of people who have recovered so far is around 12.02 percent.”

He also said that 325 districts in India have not reported any coronavirus case so far because of actions initiated at field level.

Also, the implementation of containment strategies in some districts which earlier had reported COVID-19 cases, have yielded positive results. One of such place is Puducherry’s Mahe district where no case of the infection has been reported in the last 28 days. There are 27 other districts also where no positive case has been reported in a fortnight, he said.

These 27 districts include Panipat and Rohtak in Haryana, Patna in Bihar, Nadia in West Bengal, and Wayanad and Kottayam in Kerala.

Replying to a query on whether the summer heat will hinder the spread of novel coronavirus, Dr Gangakhedkar said there is no scientific evidence at the moment to prove it.

About Congress leader Rahul Gandhi’s allegation that India was not conducting enough coronavirus tests, the ICMR said, “India tests 24 people for one positive case, while Japan tests 11.7, Italy 6.7 and US tests 5.3. So, one cannot say that India is testing less.”

At the press briefing, it was also informed that more than 16 lakh free meals have been served by the Indian Railways. Five thousand beds in 17 dedicated Railway hospitals and hospital blocks have been identified and more than 5,000 isolation coaches readied, while over 8 lakh wagons have carried supplies throughout the country.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Getting ‘voluntary action indicated’ status for Malaysian unit a key development, says Biocon’s Kiran Mazumdar Shaw

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Our public health system has to be improved and there is a lot of opportunity for us to build a very robust healthcare ecosystem, said Kiran Mazumdar Shaw, CMD, Biocon.

The USFDA has issued Establishment Inspection Report (EIR)  with ‘voluntary action indicated’ status to Biocon’s Malaysian unit in terms of production of Glargine.

Sharing further details CMD of the company Kiran Mazumdar Shaw said, “This is an important EIR that we have received and it is a good because it makes us feel confident that we will get the approval sooner than later.”

In terms of the timeline, she said, “We have always said that it will be in the first half of this year. So, that is what we stick by.”

With this entire COVID-19 crisis one does not know when the US markets will open for business. So we have to be a bit realistic, she said, adding that they were glad the inspection went well.

“I hope that we get the approval soon but in terms of the launch, we have to be realistic because we need to wait and watch and see how things progress because the US is going through a very bad phase,” she said in an interview with CNBC-TV18.

When asked about the market size, Mazumdar-Shaw said, “Post COVID-19, there will be a huge effort to bring down healthcare costs and biosimilars are certainly going to be extremely important in this effort. I believe insulin therapies are also going to play a very important role in cost cutting and biosimilar glargine, insulins and others are going to be extremely important.”

“So, we do have an opportunity to play very strongly in this segment. It is a USD 7 billion business globally and in US itself, it is a USD 4 billion business. So from that point of view, it has a huge opportunity and it is growing. With biosimilars, the access to insulin glargine is much larger. We have a very important role to play in providing affordable access to glargine,” she said.

When asked if the number of private labs conducting COVID-19 tests would be extended and the challenges that the industry is facing in India, she replied, “Including the private labs has been a very good move on part of the government. It should have been done sooner than this. The challenge is that state government’s legislations are coming in the way. The kit issue is being resolved because a number of kits are now being produced and I don’t think we will have an issue with number of kits, as more kits are being approved.”

“The biggest worry is the way state governments are restricting private labs from testing. In Karnataka, we have cleared the way. Maharashtra has become extremely difficult. All the state governments, Maharashtra, Telangana, Gujarat, West Bengal, they have come on very heavily on to private labs. If you don’t allow private labs to test large numbers, you are defeating the purpose of including private labs into this testing arena,” she cautioned.

Talking about their biologics business target of around USD 1 billion by FY22, she said, “It is two years away. We are hoping that our business will go according to plan. There has been a lull right now because of logistics issues. I am hopeful that the COVID-19 crisis will pass sooner than later. We will work towards that target but more than anything else, this is a time for biosimilars to have a huge impact on global healthcare and that is why I remain very confident that we will have a very big role to play.”

“There is a very close cooperation going on between the government, the Centre and the private sector whether it is on the research front, whether it is on the private testing front etc. I am very pleased with that. We are all working towards developing vaccines, therapies and new antibody based serological testing, so there is a lot of that kind of work going on,” she said, adding that what COVID-19 crisis has shown us is that we have to focus on these very important areas. Infectious diseases have been neglected and ignored for too long.

“Moreover, our public health system has to be improved and there is a lot of opportunity for us to build a very robust healthcare ecosystem,” she stated.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?